Denosumab (XGEVA) for hypercalcaemia of malignancy – second line
NIHR HSRIC
Record ID 32016001026
English
Authors' recommendations:
Denosumab is a drug to treat hypercalcaemia of malignancy. Hypercalcaemia is a condition in which you have too much calcium in your blood and is quite common in people who have cancer. Calcium performs important functions, such as helping to keep your bones healthy. However, too much of it can cause problems and symptoms that include sickness, constipation, confusion, and high blood pressure. Denosumab is taken as an injection under the skin and is designed to reduce the amount of calcium in the blood.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/denosumab-xgeva-for-hypercalcaemia-of-malignancy-second-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Antibodies, Monoclonal, Humanized
- Denosumab
- Hypercalcemia
- Neoplasms, Second Primary
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.